CSIMarket Company Name, Ticker, Competitors, else..
 
Tevogen Bio Holdings Inc   (NASDAQ: TVGN)
 
Price: $7.8100 $0.38 5.114%
Day's High: $7.809999942779541 Week Perf: 0.13 %
Day's Low: $ 7.51 30 Day Perf: 15.7 %
Volume (M): 2,404 52 Wk High: $ 43.65
Volume (M$): $ 0 52 Wk Avg: $13.88
Open: $7.58 52 Wk Low: $3.64



 Market Capitalization (Millions $) 30
 Shares Outstanding (Millions) 4
 Employees 18
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage specialty immunotherapy firm developing off-the-shelf, precision T cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases, cancers, and other disorders. Their proprietary ExacTcell technology produces allogeneic T cell therapies targeting multiple antigens. The lead product, TVGN 489, is focused on the treatment and prevention of COVID-19, including Long COVID. The company is advancing clinical trials, developing manufacturing capabilities, and pursuing strategic partnerships to commercialize personalized cell therapies.


   Company Address: 15 Independence Boulevard Warren 7059 NJ
   Company Phone Number: 838-6434   Stock Exchange / Ticker: NASDAQ TVGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GILD        4.12% 
IOVA        7.65% 
MRNA        29.76% 
NVAX        14.71% 
STRO        2.44% 
VXRT        4.26% 
• View Complete Report
   



Clinical Study

In a significant advancement in the field of precision medicine, Tevogen Bio Holdings Inc. (Nasdaq TVGN) ha...

Published Thu, Nov 6 2025 8:38 AM UTC

Tevogen Bio Expands HLA Coverage for Precision T Cell Therapy in Major Clinical Milestone In a significant advancement in the field of precision medicine, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced a major clinical milestone in its investigational T cell therapy program. The company reported the completion of T cell target identification for an additional five hu...
Product Service News

Tevogens Mittul Mehta to Illuminate AI Innovations at Databricks DATA + AI World Tour in Boston

Published Wed, Sep 10 2025 4:50 PM UTC

In an exciting development for both the biotechnology and artificial intelligence sectors, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) recently announced that Mittul Mehta, the company’s Chief Information Officer and Head of Tevogen.AI, will serve as a panelist at the Startup Forum during the upcoming Databricks DATA + AI World Tour, scheduled to take place in Boston on Octob...
Clinical Study

Tevogen Bios Groundbreaking Digital Leap Augmenting T Cell Therapy and Championing Health Equity,

Published Mon, Sep 8 2025 1:45 PM UTC

The Revolution in Precision Immunotherapy: Tevogen Bio s Groundbreaking Advances in Allogeneic T Cell TherapyIn the ever-evolving landscape of biotechnology, companies are racing to develop innovative therapeutic approaches that address previously unmet clinical needs. One such pioneer is Tevogen Bio Holdings Inc. (Nasdaq: TVGN), which stands at the forefront of immunothera...
Clinical Study

Tevogen Bio Highlights the Need for Targeted Immunotherapies to Combat SARS-CoV-2 in Immunocompromised Patients

Published Thu, Sep 4 2025 3:32 AM UTC

News Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 WARREN, N.J., Sept. 03, 2025 Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has taken significant strides in addressing the urgent need for effective SARS-CoV-2 treatments, particularly for individuals with compromised immune systems wh...
Product Service News

Tevogen Bio Pioneers AI-Driven Immunotherapy International Patent Publication and New Headquarters Propel Inn...

Published Sat, Jul 19 2025 11:03 AM UTC

WARREN, N.J., July 18, 2025 Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a biotech company specializing in innovative immunotherapy solutions, has made significant strides in artificial intelligence as it merges cutting-edge technology with healthcare. Recently, the International Bureau of the World Intellectual Property Organization (WIPO) published Tevogen s international ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.06
Working Capital Ratio 0.1
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.17 $
Revenues (TTM) -
Cash Flow (TTM) 0 $
Cash 0.28 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,230,069
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.